Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Rani Therapeutics Holdings (RANI – Research Report) today and set a price target of $10.00. The company’s shares closed yesterday at $7.56.
Samimy covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Jazz Pharmaceuticals, and RegenXBio. According to TipRanks, Samimy has an average return of 10.3% and a 46.85% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rani Therapeutics Holdings with a $9.75 average price target, which is a 28.97% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $13.00 price target.
Based on Rani Therapeutics Holdings’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $7.48 million. In comparison, last year the company had a GAAP net loss of $8.37 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rani Therapeutics Holdings (RANI) Company Description:
Rani Therapeutics Holdings Inc is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. It has developed the RaniPill capsule, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing.
Read More on RANI:
- Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
- Rani Therapeutics management to meet virtually with BTIG
- Rani Therapeutics price target lowered to $9 from $21 at Canaccord
- Rani Therapeutics price target lowered to $12 from $16 at H.C. Wainwright
- Rani Therapeutics reports Q4 EPS (27c), consensus (31c)
